ClinicalTrials.gg
CompletedNCT07903389crp-lcUpdated Oct 29, 2026

Comparison of Ciprofol, Remimazolam and Propofol in Laparoscopic Colorectal Surgery

An interventional study of Ciprofol and Remimazolam in Colorectal Diseases Undergoing Elective Laparoscopic Colorectal Surgery, sponsored by The First Affiliated Hospital of Zhengzhou University. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by The First Affiliated Hospital of Zhengzhou University · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 3 years 8 months after the study started (first participant enrolled Feb 2023, registered Oct 2026).
Updated Oct 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a single-center, prospective, parallel randomized controlled trial. A total of 180 patients aged 18-75 years undergoing elective laparoscopic colorectal surgery with ASA physical status Ⅰ-Ⅲ will be enrolled and randomly assigned in a 1:1:1 ratio to ciprofol group, remimazolam group or propofol group. All patients receive standardized background anesthesia regimen including dexmedetomidine, sufentanil, rocuronium and remifentanil. The primary outcome is the QoR-15 score at postoperative day 1. Secondary outcomes include intraoperative hemodynamic parameters, anesthesia recovery indicators, postoperative VAS pain scores, opioid consumption and perioperative adverse events. The study was approved by the Institutional Review Board of The First Affiliated Hospital of Zhengzhou University (approval number: 2023-KY-0137-002). Written informed consent will be obtained from each participant before enrollment.

02

Conditions studied

  • Colorectal Diseases Undergoing Elective Laparoscopic Colorectal Surgery

Keywords

  • Anesthesia; Ciprofol; Remimazolam; Propofol; Laparoscopic colorectal surgery; Postoperative recovery; QoR-15
03

In context

Lead sponsor

The First Affiliated Hospital of Zhengzhou University is the lead sponsor of 127 studies on the registry; 74 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-75 years old
  • Scheduled for elective laparoscopic colorectal surgery
  • Ⅰ-Ⅲ
  • Able to understand and complete QoR-15 assessment preoperatively

Exclusion criteria

Exclusion Criteria:

  • Severe cardiac, pulmonary, hepatic or renal dysfunction
  • Pre-existing psychiatric disease, cognitive dysfunction or inability to complete follow-up
  • Long-term history of opioid or sedative medication use
  • Known allergy to any of the study drugs
  • Postoperative ICU admission and inability to complete postoperative assessment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    Ciprofol group (C group)

    Patients receive ciprofol for anesthesia induction and maintenance. Induction: ciprofol 0.4 mg/kg IV; maintenance: 0.8-2.0 mg/kg/h continuous infusion. All patients receive standardized anesthesia background regimen including dexmedetomidine, sufentanil, rocuronium, remifentanil. Postoperative standardized PCIA is applied.

    Drug: Ciprofol

  • Experimental
    Remimazolam group (R group)

    Patients receive remimazolam for anesthesia induction and maintenance. Induction: remimazolam 12 mg/kg/h IV; maintenance: 1-2 mg/kg/h continuous infusion. All patients receive standardized anesthesia background regimen including dexmedetomidine, sufentanil, rocuronium, remifentanil. Postoperative standardized PCIA is applied.

    Drug: Remimazolam

  • Experimental
    Propofol group (P group)

    Patients receive propofol for anesthesia induction and maintenance. Induction: propofol 1.5-2.0 mg/kg IV; maintenance: 4-12 mg/kg/h continuous infusion. All patients receive standardized anesthesia background regimen including dexmedetomidine, sufentanil, rocuronium, remifentanil. Postoperative standardized PCIA is applied.

    Drug: Propofol

Interventions

  • Ciprofol injection, intravenous anesthesia induction and maintenance for laparoscopic colorectal surgery.

  • Remimazolam injection, intravenous anesthesia induction and maintenance for laparoscopic colorectal surgery.

  • Propofol injection, intravenous anesthesia induction and maintenance for laparoscopic colorectal surgery.

06

What researchers measure

Primary outcomes

  1. Postoperative Quality of Recovery Scale-15 (QoR-15) score

    QoR-15 consists of 15 items covering 5 domains: pain, physical comfort, emotional state, psychological support, and physical independence. Total score ranges from 0 to 150; higher score indicates better postoperative recovery. Assessed at postoperative day 1.

    Time frame: Postoperative day 1

Secondary outcomes

  1. Mean arterial pressure (MAP)

    Description: Mean arterial pressure measured during perioperative period

    Time frame: Before anesthesia induction, After tracheal intubation, 30 minutes after surgical incision, At the end of surgery, At extubation

  2. Cough Visual Analogue Scale (VAS) pain score

    Cough-induced visual analogue scale (VAS) pain scores were assessed at 6 hours, 12 hours, 24 hours, and 48 hours postoperatively. Cumulative opioid consumption was recorded at 24 hours and 48 hours after surgery. The VAS score ranges from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain.

    Time frame: 6, 12, 24, and 48 hours after surgery

  3. Perioperative adverse events

    Incidence of hypotension, bradycardia, postoperative nausea and vomiting, respiratory depression, delayed emergence, postoperative delirium.

    Time frame: From anesthesia induction to 48 hours postoperatively

07

Study locations

1 site
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
08

References and documents

Publications

  • Liu Z, Hong J, Huang X, Wu D. Olfactory cleft mucus galectin-10 predicts olfactory loss in chronic rhinosinusitis. Ann Allergy Asthma Immunol. 2023 Mar;130(3):317-324.e1. doi: 10.1016/j.anai.2022.07.014. Epub 2022 Jul 21. PubMed 35870756 ↗
  • Gondalia V, Choi DH, Lee SC, Nam CH, Hwang BH, Ahn HS, Ong AC, Park HY, Jung KA. Periprosthetic supracondylar femoral fractures following total knee arthroplasty: clinical comparison and related complications of the femur plate system and retrograde-inserted supracondylar nail. J Orthop Traumatol. 2014 Sep;15(3):201-7. doi: 10.1007/s10195-014-0287-x. Epub 2014 Apr 1. PubMed 24687558 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) including baseline characteristics, intraoperative hemodynamic data, postoperative recovery scores, pain scores and adverse event data will be available upon reasonable request after publication of the primary results. The data will be shared after completion of the study and publication of the main manuscript. Requests should be directed to the principal investigator. Data will be provided after signing a data access agreement.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2023 to primary completion in Dec 2024, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2026
First posted
Oct 29, 2026
StartActual
Feb 1, 2023
Primary completionActual
Dec 31, 2024
CompletionActual
Dec 31, 2024
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07903389
Responsible party
Du Yingying (doctor, The First Affiliated Hospital of Zhengzhou University) — Principal investigator
First posted
Oct 29, 2026
Start date
Feb 1, 2023
Primary completion
Dec 31, 2024
Completion
Dec 31, 2024
Last update
Oct 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ciprofol · Remimazolam · Propofol

Start the discussion